Circulating FK506 Binding Protein 51 MRNA Expression in Patients with Pituitary Adenomas

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Jan 26

PMID 36699264

Authors

Yingying Yang

Lilit Babayan

Argishty Mirzakhanian

Nvard Sisliyan

Dongyun Zhang

Carolina Hurtado

Abdul Zahid

Marvin Bergsneider

Won Kim

Marilene B Wang

Anthony P Heaney

Affiliations

Soon will be listed here.

Abstract

Background: FK506 binding protein 51 (FKBP5) is a co-chaperone regulator of the glucocorticoid receptor (GR). Recent studies have reported increased FKBP5 mRNA in the circulation from patients with Cushing disease (CD) which returned to comparable levels seen in healthy controls following successful -nasal -sphenoidal (TNTS) surgical corticotroph tumor removal. However, the expression of circulating FKBP5 mRNA levels in other pituitary tumor subtypes and its specificity to corticotroph tumors is unknown.

Methods: Pre-operative blood was collected from consecutive patients undergoing TNTS for pituitary tumors (n = 57) at our center between 2015 and 2019. Total RNA was isolated from whole blood using RiboPure blood RNA isolation kit and real-time qPCR was used to quantitate circulating FKBP5 mRNA expression.

Results: Consistent with the prior report, higher circulating FKBP5 mRNA levels were observed in 20 patients with CD prior to surgical tumor removal, compared to 21 healthy controls (p < 0.0005) and compared to 8 patients harboring gonadotroph pituitary tumors (p < 0.05) and 6 patients with silent corticotroph pituitary tumors (p < 0.05). However, circulating FKBP5 mRNA levels were higher in 10 patients with prolactin (PRL)-secreting pituitary tumors compared to healthy controls (p < 0.05), and did not differ between patients with CD and patients with growth hormone secreting tumors (GH-omas).

Conclusions: Although we confirm that circulating FKBP5 mRNA is higher in patients with corticotroph tumors compared to healthy subjects, measurement of circulating FKBP5 does not appear to be helpful to distinguish corticotroph tumors from other pituitary tumor sub-types.

References

Rao S, Yao Y, Ryan J, Li T, Wang D, Zheng C . Common variants in FKBP5 gene and major depressive disorder (MDD) susceptibility: a comprehensive meta-analysis. Sci Rep. 2016; 6:32687. PMC: 5013409. DOI: 10.1038/srep32687. View

Binder E, Salyakina D, Lichtner P, Wochnik G, Ising M, Putz B . Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004; 36(12):1319-25. DOI: 10.1038/ng1479. View

Binder E, Bradley R, Liu W, Epstein M, Deveau T, Mercer K . Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA. 2008; 299(11):1291-305. PMC: 2441757. DOI: 10.1001/jama.299.11.1291. View

Nieman L, Biller B, Findling J, Newell-Price J, Savage M, Stewart P . The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 93(5):1526-40. PMC: 2386281. DOI: 10.1210/jc.2008-0125. View

Fujii T, Ota M, Hori H, Hattori K, Teraishi T, Matsuo J . The common functional FKBP5 variant rs1360780 is associated with altered cognitive function in aged individuals. Sci Rep. 2014; 4:6696. PMC: 4204028. DOI: 10.1038/srep06696. View

Menke A, Klengel T, Rubel J, Bruckl T, Pfister H, Lucae S . Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav. 2013; 12(3):289-96. DOI: 10.1111/gbb.12026. View

Kinouchi S, Iga J, Ueno S, Yamauchi K, Numata S, Song H . FKBP5, SERT and COMT mRNA expressions in the peripheral leukocytes during menstruation cycle in healthy reproductive females. Neurosci Lett. 2008; 434(1):124-8. DOI: 10.1016/j.neulet.2008.01.039. View

Bancos I, Hatipoglu B, Yuen K, Chandramohan L, Chaudhari S, Moraitis A . Evaluation of FKBP5 as a cortisol activity biomarker in patients with ACTH-dependent Cushing syndrome. J Clin Transl Endocrinol. 2021; 24:100256. PMC: 8260880. DOI: 10.1016/j.jcte.2021.100256. View

Stamm T, Rampp C, Wiethoff K, Stingl J, Mossner R, O Malley G . The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. J Psychopharmacol. 2015; 30(1):40-7. DOI: 10.1177/0269881115620459. View

10.

Hinojosa-Amaya J, Johnson N, Gonzalez-Torres C, Varlamov E, Yedinak C, McCartney S . Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Front Endocrinol (Lausanne). 2020; 11:579606. PMC: 7652723. DOI: 10.3389/fendo.2020.579606. View

11.

Ioachimescu A, Fleseriu M, Hoffman A, Vaughan Iii T, Katznelson L . Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2018; 180(1):31-40. DOI: 10.1530/EJE-18-0682. View

12.

Findling J, Raff H . DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome). Eur J Endocrinol. 2017; 176(5):R205-R216. DOI: 10.1530/EJE-16-0946. View

13.

Szczepankiewicz A, Leszczynska-Rodziewicz A, Pawlak J, Narozna B, Rajewska-Rager A, Wilkosc M . FKBP5 polymorphism is associated with major depression but not with bipolar disorder. J Affect Disord. 2014; 164:33-7. DOI: 10.1016/j.jad.2014.04.002. View

14.

Wochnik G, Ruegg J, Abel G, Schmidt U, Holsboer F, Rein T . FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem. 2004; 280(6):4609-16. DOI: 10.1074/jbc.M407498200. View

15.

Zannas A, Wiechmann T, Gassen N, Binder E . Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications. Neuropsychopharmacology. 2015; 41(1):261-74. PMC: 4677131. DOI: 10.1038/npp.2015.235. View

16.

Ising M, Maccarrone G, Bruckl T, Scheuer S, Hennings J, Holsboer F . FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression. Int J Mol Sci. 2019; 20(3). PMC: 6387218. DOI: 10.3390/ijms20030485. View

17.

Binder E . The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009; 34 Suppl 1:S186-95. DOI: 10.1016/j.psyneuen.2009.05.021. View

18.

Hameed N, Yedinak C, Brzana J, Gultekin S, Coppa N, Dogan A . Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary. 2012; 16(4):452-8. DOI: 10.1007/s11102-012-0455-z. View